Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

SYK inhibitor

DRUG CLASS:

SYK inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	HM43239 Sensitive: B - Late Trials HM43239 Sensitive : B	HM43239 Sensitive: B - Late Trials HM43239 Sensitive : B
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	GS-9973 Sensitive: C2 – Inclusion Criteria GS-9973 Sensitive : C2	GS-9973 Sensitive: C2 – Inclusion Criteria GS-9973 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	GS-9876 Sensitive: C2 – Inclusion Criteria GS-9876 Sensitive : C2	GS-9876 Sensitive: C2 – Inclusion Criteria GS-9876 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	GS-9973 Sensitive: C2 – Inclusion Criteria GS-9973 Sensitive : C2	GS-9973 Sensitive: C2 – Inclusion Criteria GS-9973 Sensitive : C2
KRAS mutation	Childhood B Acute Lymphoblastic Leukemia	KRAS mutation	Childhood B Acute Lymphoblastic Leukemia	GS-9973 Resistant: C3 – Early Trials GS-9973 Resistant : C3	GS-9973 Resistant: C3 – Early Trials GS-9973 Resistant : C3
NRAS mutation	Childhood B Acute Lymphoblastic Leukemia	NRAS mutation	Childhood B Acute Lymphoblastic Leukemia	GS-9973 Resistant: C3 – Early Trials GS-9973 Resistant : C3	GS-9973 Resistant: C3 – Early Trials GS-9973 Resistant : C3
HOXA9 overexpression + MEIS1 overexpression	Acute Myelogenous Leukemia	HOXA9 overexpression + MEIS1 overexpression	Acute Myelogenous Leukemia	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3
MEIS1 overexpression	Acute Myelogenous Leukemia	MEIS1 overexpression	Acute Myelogenous Leukemia	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3
HOXA9 overexpression	Acute Myelogenous Leukemia	HOXA9 overexpression	Acute Myelogenous Leukemia	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3
SF3B1 mutation	Chronic Lymphocytic Leukemia	SF3B1 mutation	Chronic Lymphocytic Leukemia	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3
NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3